1992
CPDR established by US Congress Public Law 102–172
1993
CPDR Basic Science Research Program established at the USU Department of Surgery
Collaborative program with AFIP initiated, focusing on biospecimens
1994
CPDR reported p53 and AR discoveries in advanced prostate cancer
Started urology resident rotation in cancer molecular biology
1995
CPDR reported finding that African American men have higher PSA values
CPDR defined the role of p53 in prostate cancer progression and gene therapy strategies
1996
CPDR Multicenter National Database Study initiated
1997
Developed optimized PSA screening guidelines for African American men, published in NEJM
1998
Developed internet-based prognostic model for prostate cancer
Discovery of a novel prostate specific non-coding RNA gene, PCGEM11999
Grand opening of the CPDR, Department of Surgery, USU building in Rockville, MD
Opening of CPDR Comprehensive Prostate Disease Clinical Care Center at WRNMMC
CPDR awarded NIH R01 grant to study the prostate cancer gene PCGEM1
Established the Prostate Cell Center for the development of new cell culture models
CPDR received two DoD/CDMRP grants to study 1) PSGR gene and 2) an internet-accessible prognostic nomogram
Established the Multi-Disciplinary Prostate Cancer Clinic
Started the DoD’s first Prostate Cancer Quality of Life Study for military beneficiaries
CPDR awarded NIH R01 grant to study the cell-specific gene expression signatures in prostate cancer
CPDR discovery of ERG as one of the most common prostate cancer-causing genes published in Oncogene
CPDR prostate cancer gene panel licensed to Gen-Probe Inc. and CRADA was established
CPDR awarded NIH R01 grant to study the PMEPA1 gene (novel regulator of androgen receptor)
CPDR awarded DoD-PCRP grant to study new aspects of the ERG oncogene function
CPDR reported new mechanism and therapeutic potential of ERG oncogene involving C-MYC
CPDR received DoD/CDMRP award to train researchers under the HBCU Students Summer Research Training Program
CPDR developed first monoclonal antibody for evaluating ERG oncoprotein in prostate cancer
2010
CPDR, Department of Surgery, USU designated as the Prostate Cancer Center of Excellence by DOD
CPDR reported first evaluation of ERG oncoprotein in prostate cancer
2011
CPDR’s ERG monoclonal antibody licensed by Biocare Medical Inc. for worldwide distribution for pathologic evaluations of prostate cancer
2012
CPDR published study on differences in ERG frequency between Caucasian American and African American prostate cancer patients
Exosome Diagnostics licensed two CPDR patents on ERG and other prostate cancer-related genes
2013
CPDR awarded three grants: DoD/PCRP-Health Disparity, USU-JOTT, and USMCI
CPDR launched CRADA with Genomic Health Inc. and Berg Pharma
2014
CPDR awarded three grants: DoD/PCRP-HBCU Training Award, MCC-Translational Research Fellowship Award, and USU-JOTT IP Development Award
2015
CPDR discovered recurrent genomic deletion in prostate cancer among African American patients
CPDR awarded two grants: DoD/PCRP-Health Disparity and CCR/NCI-MCC
2016
CPDR joined Murtha Cancer Center organization structure
Clinical application of the ExoDX PCa urine assay initiated
2017
Oncotype DX Prostate Cancer test (i.e., part of NCCN diagnostic guidelines) validated at CPDR
New ERG inhibitor patented
2018
CPDR received College of American Pathologists (CAP) Biorepository Accreditation
Following DHA guidance, CPDR Biobank transferred to the MCC Biobank at Windber, PA
2019
New, state-of-the-art CPDR laboratory facility and workspace opened in Bethesda, MD
2020
CPDR investigators collaborated on prostate cancer germline testing guidelines, developed as part of the Philadelphia Prostate Cancer Consensus Conference
2021
CPDR published study on non-invasive urine exosome-based assay for early detection of high-grade prostate cancer
CPDR investigators contributed to study on genetic risk prediction using GWAS in a large, diverse cohort
2022
CPDR published study on DNA damage repair inherited mutations in African American men with prostate cancer
Prognosis of prostate cancer progression to metastasis in relation to p53 expression reported by CPDR investigators
2023
CPDR investigators contributed to study on genetic risk prediction by GWAS in a large, multi-ancestry cohort
Artificial intelligence-based evaluation of digitized whole mount prostate slides initiated in multi-institutional collaboration between CPDR, JPC and NCI
2024
Artificial intelligence-based whole mounted prostate evaluation published